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Abstract
In 2000, more than 151 million people in the world are diabetic. It is predicted that by 2010, 221
million people and by 2025, 324 million will be diabetic. In the U.S., for the population born in 2000,
the estimated lifetime risk for diabetes is more than 1 in 3. The economic and human cost of this
disease is devastating. The current cost of diabetes in the U.S. is estimated to be at $132 billion,
which includes $92 billion of direct medical costs and $40 billion of indirect costs such as disability,
work loss and premature mortality. The outbreak of the current diabetic epidemic has been
accompanied by a similarly drastic increase in obesity. The relation between the two is a matter of
debate but presumably both are caused by changes in dietary habits and an increasingly sedentary
modern lifestyle. Compelling scientific evidence indicates that lifestyle modification effectively
prevents or delays the occurrence of type 2 diabetes. Recent clinical trials also demonstrate that
success in the treatment of obesity, either surgically or pharmacologically, leads to the prevention
of type 2 diabetes among the obese. Clinical data have also revealed that the insulin sensitizing agent
troglitazone is efficacious in both β-cell preservation and delaying the onset of type 2 diabetes.
Future safe and more effective anti-obesity medicines and insulin sensitizing agents that help to
preserve β-cell function, in addition to efforts of lifestyle modification, thus hold promise for the
overweight population with potential for reduction in the development of diabetics.
Background
Social affluence is a double edged sword. On the one
hand, life is more convenient than ever because of the
advances in technology; on the other hand, the incidence
of diabetes is occurring at an alarming rate. The explosive
increase in number of people diagnosed with diabetes
makes this disease a new health threat in the 21st century.
Understanding the etiology of and finding a way to pre-
vent diabetes, especially type 2 diabetes, is an urgent chal-
lenge for the health care community and our society.
Epidemics of type 2 diabetes
In 2002, more than 18 million Americans, about 6.9% of
the U.S. population, have diabetes [1]. Globally, the
number of people that has been diagnosed with diabetes
has also exploded in the past two decades. In 2000, 151
million people in the world were diabetic. With the cur-
rent rate of increase, it has been projected that 221 million
people will be diabetic in 2010 and 324 million by 2025
[2].
There are two major forms of diabetes: type 1 and type 2
diabetes [3]. The hall mark of type 1 diabetes is the
destruction of insulin producing β-cells in the pancreas,
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primarily due to autoimmune responses. Type 1 diabetes
is manifested with absolute insulin deficiency. In contrast,
type 2 diabetes is characterized by two defects: insulin
deficiency and insulin resistance. Type 2 diabetes accounts
for 90 to 95% of the incidence of diabetes. The current
epidemic outbreak of diabetes reflects the high prevalence
of type 2 diabetes.
While the seriousness of the epidemic was only fully rec-
ognized recently, the threat by a trend of the increase of
incidences in diabetes was first recognized by Elliott Joslin
some 80 years ago [4]. From a historical perspective, the
epidemic of type 2 diabetes today has developed steadily
through the decades in the last century. According to the
data of National Health Interview Survey, the incidence in
1990–1992 was 6.4 times the rate of 1935–1936 [5]. In a
10-year span from 1990 to 1999, the prevalence further
increased by 40% from 4.9% to 6.9% [6]. Assuming the
rate of increase in incidences continues, the data from the
National Health Interview Survey (1984–2000) predicts
that the residual lifetime risk of diabetes for individuals
born in 2000 is 32.8% for males and 38.5% for females.
The highest risk for ethnic subpopulations is in Hispanic
females whose lifetime risk of becoming diabetic is 52.5%
[6].
The global statistics indicate that the burden of type 2 dia-
betes is not restricted to the developed nations, but also is
a problem for developing countries. For example, in the
Pacific island of Nauru, type 2 diabetes is present in about
40% of adults [7]. Ironically this disease was not present
a half century ago in this region. In a 11-year follow-up
study in Mauritius, the prevalence of type 2 diabetes, in
both men and women, regardless of ethnic group,
increased steadily from 12.8% in 1987, to 15.2% in 1992,
and to 17.9% in 1998 [8]. In recent years, the prevalence
of type 2 diabetes has also increased in world's two largest
populated nations, China [9] and India [10]. India now
has the most people – 38 million – with diabetes. China
is ranked second and has 23 million diabetics. By 2025,
these numbers are expected to be doubled to about 73
million and 46 million, respectively [11].
Although previously type 2 diabetes was predominantly
diagnosed in middle-aged or older people, the age of
onset of this disease has decreased. Japan has seen an
approximately 4-fold rise in the incidence of type 2 diabe-
tes in 6- to 15-year-olds. This rate now is outnumbering
that of type 1 diabetes in that country [11]. Data from the
U.S. indicates that 8–45% of recently diagnosed cases of
diabetes in the young is due to type 2 diabetes [12].
Uncontrolled diabetes leads to other serious medical
complications including a substantial increase in prema-
ture morbidity and mortality [13,14]. It is reported that
the incidence of cardiovascular disease among adult dia-
betics is 37.2%, which is much higher than the incidence
in the general population [14]. Prevalence of ischemic
heart disease among the diabetics 18 to 44 years of age is
14 times for those without diabetes [14]. The high blood
glucose of diabetes also causes both micro and macro vas-
cular damages. Damages in large vessels lead to stroke and
cardiovascular complications, whereas damages to vessels
in the extremities, eyes and kidneys lead to amputation,
blindness and kidney failure. As a result, each year, as
many as 24,000 diabetics in the U.S. become blind [14];
more than 100,000 require kidney dialysis or kidney
transplantation which accounts for more than 40% of
new cases of end-stage renal disease. Furthermore, 82,000
diabetics need to have a toe or a leg amputated, account-
ing for more than half of all non-traumatic lower-extrem-
ity amputations in the U.S. [14]. The diabetes epidemic is
thus a large assault on the health care system and a huge
burden for the society. The current cost of diabetes in the
U.S. is estimated as $132 billion, which includes direct
medical costs of $92 billion and indirect costs (disability,
work loss, premature mortality) of $40 billion [1].
Obesity, Metabolic Syndrome, prediabetes
Obesity
What is the driving force for the current worldwide epi-
demic of diabetes? Environmental factors such as adop-
tion of a sedentary lifestyle, changes in eating habits and
consequent obesity, are likely the main causes or at least a
parallel problem. This hypothesis is supported strongly by
the studies in migrating populations. For example, the
prevalence of diabetes in the urban regions of India is
increasing dramatically in affluent migrant Indians [15].
Rates among Asian Indians in countries such as South
Africa, the U.K. and Fiji are much higher than reported in
most parts of India itself [16]. The incidence is also rising
among Africans who have either urbanized or immigrated
to the U.S. [17,18]. Before the 1990s, the rates of type 2
diabetes in Japan were quite low; but high rates were
found in Japanese living in the U.S. [16]. Rates of
increased incidence of diabetes in populations of Chinese
origin also vary with environment changes. In the North-
ern part of mainland China, in the age group 30 to 64,
about 1% was the rate for type 2 diabetes; this number
went to 4 to 5% among the Chinese in Singapore and to
11 to 12% in Mauritus [19]. Many native American Indian
tribes have a higher prevalence of diabetes as compared
with the general U.S. population; but Eskimos appears to
be an exception, whose diabetes rate is not distinct from
white Americans [20]. All these population-based studies
reveal a similar pattern: environmental changes and adap-
tation of sedentary lifestyle, resulting from industrializa-
tion and migration to urban cities, lead to the
development of type 2 diabetes.Nutrition & Metabolism 2005, 2:29 http://www.nutritionandmetabolism.com/content/2/1/29
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Parallel to the increase of incidences in type 2 diabetes is
the increase of obesity in the population. According to the
definition recommended by the World Health Organiza-
tion (WHO) expert committee for the classification of
overweight and obesity, today, close to 65% of the U.S.
adult population is overweight, and among them, above
30% are obese [21]. In this classification, Body Mass Index
(BMI) between 25 to 30 is considered as overweight and
BMI above 30 is considered as obese. Based on the statis-
tics collected by National Health and Nutrition Examina-
tion Survey (NHANES), in a representative sample of the
U.S. population, the prevalence of an overweight condi-
tion has increased by 40% (from 46% in the period of
1976–1980 to 64.5% in the period of 1999–2000), and
the prevalence of obesity has increased by 110% (from
14.5% to 30.5%) [21,22]. In addition, the increase in
weight in the young population also exhibits an alarming
growth. If overweight is defined as at or above the 95th
percentile of the sex-specific BMI for age growth charts,
among those aged 2 through 19 years, the prevalence of
overweight was 15.5% among 12-through 19-year-olds,
15.3% among 6-through 11-year-olds, and 10.4% among
2-through 5-year-olds according to 1999–2000 NHANES
data. These numbers are significantly increased from
10.5%, 11.3%, and 7.2%, respectively, as collected in
1988–1994 (NHANES III).
Despite the on-going debate as to whether obesity should
be labeled as a disease, obesity, directly and indirectly, has
become the global health challenge. It has been estimated
that close to 300,000 deaths each year in the U.S. may be
attributable to obesity [23]. In a study comparing health
care spending on obese and normal-weight Americans
between 1997 and 2001, it was found that per capita
spending for the obese was more than $1000, or 37%,
higher than spending on normal-weight people in 2001
[24].
Obesity has become a burden for society, as it is a major
cause of lost productivity. The financial burdens that are
consequences of obesity are associated with the treatment
needed for the accompanying disease states, such as cardi-
ovascular disease, cancer, hypertension, and most inti-
mately, to type 2 diabetes [25]. In a 16-year follow-up
study of 84,941 women, it was documented that 3300
new cases of type 2 diabetes were diagnosed from 1980 to
1996 [26]. Among these cases, body weight was the single
most important predictor of diabetes. As high as ~80% of
the cases of type 2 diabetes could be attributed to the com-
bined effect of inactivity and high body weight [27].
In the realm of lifestyle, the change of dietary composi-
tion, in addition to the total caloric intake, is probably
another important factor that is implicated in the epidem-
ics of type 2 diabetes. For example, one important but not
well-appreciated dietary change has been the substantial
increase in refined carbohydrates especially simple carbo-
hydrate from high intake of sucrose and high fructose
corn syrup, a common sweetener used in the food indus-
try. High influx of carbohydrate is predicted to drive the
increase of de novo hepatic lipogenesis and perturbs the
glucose homeostasis that appear to underlie the induction
of insulin resistance [28,29].
The exact molecular and cellular connection between
obesity and type 2 diabetes has not been entirely
explained. In particular, there is no unifying hypothesis
that explains the various states of "garden-variety" insulin
resistance associated with diet-induced obesity. One of
the hypotheses highlights the pathological roles of lipid
abnormality accompanying obesity or high body weight,
postulates that accumulation of fatty acids or fatty acid
derivatives in muscle and liver produce insulin resistance
[30]. At the cellular level, it has been proposed that the
accumulation of diacylglycerol might activate protein
kinase C (PKC) (probably by PKC-θ in rodents and by
PKC-β or -δ in humans) [31]. The activated PKC in turn
phosphorylates and activates other serine kinases such as
IKK-β[32]and JNK-1 [33], leading to phosphorylation of
serine sites on IRS-1 insulin receptor substrate (IRS) 1 and
2 at Serine/Threonine sites, blunting the insulin signaling
pathway[34]. It is also suggested that ceramide, a down
stream product of fatty acid metabolism, down regulates
insulin signaling in muscle [35]. It has been shown that
ceramide blocks insulin-stimulated tyrosine phosphoryla-
tion of IRS-1 and its subsequent recruitment and activa-
tion of PI3 kinase. The abnormalities in fat metabolism
and insulin resistance seem to form a vicious cycle. Hyper-
insulemia from elevated caloric or carbohydrate intake
especially in the presence of high fat may cause insulin
resistance in adipocytes leading to elevated fatty acids
which, in turn may cause insulin resistance in muscle. At
the same time, insulin resistance further exacerbates the
abnormalities in hepatic fat metabolism [36,37]. In addi-
tion to the adverse metabolic consequences in insulin
sensing tissues, fat accumulation also has harmful effects
in insulin producing β-cells. The increased tissue levels of
fatty acyl CoA cause β-cell abnormalities in nondiabetic
obese patients and ultimately result in obesity-dependent
diabetes [38]. Of note, these potential mechanisms are
not mutually exclusive. In fact, they could all play roles at
various stages for the development of type 2 diabetes, a
long and gradual process [39].
Metabolic Syndrome
Obesity and insulin resistance often coexist along with
other abnormalities such as hypertension and dyslipi-
demia. In 1988, Reaven introduced the concept of Meta-
bolic Syndrome X in the Banting Medal address, in order
to emphasize the coexistence of multiple metabolicNutrition & Metabolism 2005, 2:29 http://www.nutritionandmetabolism.com/content/2/1/29
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abnormalities. This term underscores the fact that insulin
resistance and its compensatory hyperinsulinemia
develop with dysregulation of glucose and lipid metabo-
lism [40]. The dysregulation of glucose metabolism is rep-
resented by varying degree of glucose tolerance. The
dysregulation of metabolism of lipid is manifested by the
increase of plasma triglyceride levels and the decrease of
plasma HDL cholesterol. Numerous population-based
studies have described the characteristics of Metabolic
Syndrome X. Considerable information has evolved from
the original recognition of the clustering of metabolic
abnormalities centering around insulin resistance/hyper-
insulinemia. The original term Metabolic Syndrome X has
become a synonym of Insulin Resistance Syndrome or
Metabolic Syndrome. Currently, the abnormalities clus-
tered with insulin resistance include some degree of glu-
cose intolerance (either manifested as elevated fasting
glucose or impaired glucose tolerance), dyslipidemia (ele-
vated triglycerides, reduced HDL-c, reduced LDL-particle
diameter), endothelial dysfunction (increased mononu-
clear cell adhesion, cellular adhesion molecules and
decrease in endothelial-dependent vasodilatation),
increased procoagulant factors, and elevation of inflam-
mation [41].
The Third Report of the National Cholesterol Education
Program Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) (ATP III) has provided a working def-
inition of the syndrome for the first time. Individuals hav-
ing three or more of the following criteria were defined as
having the metabolic syndrome: 1) abdominal obesity:
waist circumference > 102 cm in men and > 88 cm in
women; 2) hypertriglyceridemia: ≥ 150 mg/dL; 3) low
HDL cholesterol: < 40 mg/dL in men and < 50 mg/dL in
women; 4) high blood pressure: ≥ 130/85 mm Hg; 5) high
fasting glucose: ≥ 110 mg/dL [42]. World Health Organi-
zation has defined metabolic syndrome in the following
way: at least 1 of abnormalities in glycemic metabolism
(type 2 diabetes, impaired glucose tolerance, insulin
resistance) accompanied by at least 2 other conditions:
high blood pressure (≥ 140/90 mm Hg), obesity, dyslipi-
demia (hypertriglyceridemia or low HDL) and microalbu-
minuria [43]. (For comparison of the differences between
the two definitions, see Table 1). The subtle differences
among various definitions do not change the overall con-
clusion that the prevalence of metabolic syndrome is
high. It has been estimated, using ATP III criteria, that the
prevalence in the U.S. population was 21.8% between
1988–1994. Using 2000 census data, about 47 million
U.S. residents are estimated to have the metabolic syn-
drome [44].
Since the introduction of the concept of Metabolic Syn-
drome and the subsequent accumulation of large body of
research data, it is beyond doubt that metabolic abnor-
malities in the areas of carbohydrate metabolism, body
weight homeostasis, lipid metabolism and blood pressure
regulation, tend to occur concomitantly. However, the
precise criteria for the definition of Metabolic Syndrome
has yet to be unified. This is probably due to the enor-
mous complexity of physiological/pathological condi-
tions that Metabolic Syndrome covers. As such, the
clinical utility and value of diagnosing Metabolic Syn-
drome is debated [45,46]. In a recent Joint Statement
from the American Diabetes Association and the Euro-
pean Association, it is stated that "Our analysis indicates
that too much critically important information is missing
to warrant its designation 'syndrome'. Until much needed
research is completed, clinicians should evaluate and treat
all CVD risk factor without regard to whether a patient
meets the criteria for diagnosis of the 'metabolic syn-
drome"'[47].
Prediabetes
Epidemiological studies indicate that the development of
type 2 diabetes takes place over a long period of time from
the initial decline of insulin effectiveness ultimately pro-
Table 1: Definition of the Metabolic Syndrome.
ATP III Definition
Any three or more of the following criteria:
a) Waist circumference: >102 cm in men, >88 cm in women
b) Serum triglycerides: ≥ 150 mg/dL
c) HDL-cholesterol: <40 mg/dL in men, < 50 mg/dL in women
d) Blood pressure: ≥ 130/85 mm Hg
e) Serum glucose: >110 mg/dL
WHO Definition
Diabetes or IFG or IGT or insulin resistance, plus at least two of the following criteria
a) Waist-to-hip ratio: >0.90 in men, >0.85 in women
b) Serum triglycerides: >150 mg/dL par or HDL-cholesterol: <35 mg/dL in men and <40 mg/dL in women
c) Blood pressure: >140/90 mmHg
d) Urinary albumin excretion rate > 20 ug/min or albumin/creatinine ratio >30 mg/gNutrition & Metabolism 2005, 2:29 http://www.nutritionandmetabolism.com/content/2/1/29
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gressing to frank diabetes when β-cell function collapses.
In most patients, insulin resistance can be detected long
before the deterioration of glucose intolerance occurs.
Approximately 5 to 10% of glucose-intolerant patients
progress to frank type 2 diabetes in a given year. Inasmuch
as Metabolic Syndrome emphasizes the condition of insu-
lin resistance, the syndrome itself is not type 2 diabetes,
but a large percentage of the people with Metabolic Syn-
drome will develop type 2 diabetes if the condition of
insulin sensitivity is not improved. While the confident
diagnosis of Metabolic Syndrome is technically difficult
because the criteria are elusive, a simpler term – prediabe-
tes – was introduced to define patients who have modestly
higher glucose levels than normal but have not yet
reached diabetic glucose levels. There are two criteria for
prediabetes: impaired glucose tolerance (IGT) or impaired
fasting glucose (IFG). The American Diabetes Association
(ADA) specifies as a 2-h postprandial glucose 140 – 199
mg/dL as IGT, and fasting plasma glucose 110 – 125 mg/
dL as IFG [48]. In 2005, in the U.S. alone, 41 million
adults are reported to have prediabetes [49].
The big question is when the diabetes clock starts ticking.
For eye or small vessel complication, it might be the con-
sequence of increased plasma glucose level. For cardiovas-
cular disease, however, the risk likely starts in the
prediabetes stage. Subjects with IFG have been demon-
strated to have an increased risk for macrovascular dis-
ease, in a variety of population-based studies [50,51].
Thus insulin resistance has been considered as an inde-
pendent risk factor for the cardiovascular disease. Because
of this, the detection of IGT is of great importance for gen-
eral public health, in particular to help prevent cardiovas-
cular complications in the high risk population [52].
Although the definition of prediabetes is simpler than
Metabolic Syndrome, the glucose tolerance test remains a
time-consuming method. IFG can not replace the toler-
ance test, since each test may reflect different defective
conditions of glucose metabolism. Because the glucose
tolerance test is difficult to implement as a population
screen test, a large number of people have been left undi-
agnosed and unaware of the risks they face. This is partic-
ularly true for people who are overweight. Based on
NHANES III data, among the overweight adults in the
U.S., 17.1% aged 45–74 years had IGT, 11.9% had IFG,
22.6% had prediabetes, and 5.6% had both IGT and IFG.
It is estimated that in the year 2000, 9.1 million over-
weight adults aged 45–74 had IGT, 5.8 million had IFG,
11.9 million had prediabetes, and 3.0 million had IGT
and IFG [53].
The genetics of type 2 diabetes and obesity
The search of human genetic factor(s) that predispose to
type 2 diabetes and obesity has gone through two direc-
tions: by studying of rare mutations and by population-
based gene-hunting for the primary causes [54-56]. It is
generally accepted, after more than 20 years of intense
effort, that environmental factors such as lifestyle and die-
tary composition play profound roles for the pathogenesis
of type 2 diabetes and obesity. Furthermore, it is a consen-
sus in the field that type 2 diabetes and obesity are poly-
genic diseases. As such, the population based gene-
Table 2: Mendelian causes of type 2 diabetes and obesity
Type 2 diabetes
Mutations Gene Names Reference
ABCG8 ATP-binding cassette Subunit C [97, 98]
CAPN10 Calpain 10 [99, 100]
GCGR Glucagon receptor [101]
GCK Glucokinase [102]
KCNJ11 Potassium channel subunit J, member 11 [103]
PPARG Peroxisome proliferator-activated receptor γ [104]
HNF4A Hepatocyte nuclear factor 4α [105]
HNF1A Hepatocyte nuclear factor 1α [106]
SLC2A1 Glut 1 [107]
INS Insulin [108]
INSR Insulin receptor [109, 110]
Mitochondrial genome Mitochondrial DNA [111]
Obesity
Diabetes Leptin receptor [112]
Mc4r Melanocortin-4 receptor [113]
Obese Leptin [114]
PCSK1 Prohormone convertase 1 [115]
Pomc Pro-opiomelanocortin [116]
SLC6A14 Solute carrier family 6 member 14 [117]Nutrition & Metabolism 2005, 2:29 http://www.nutritionandmetabolism.com/content/2/1/29
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hunting efforts have not yielded conclusive "diabe-
togenes" and "obesitogenes". In contrast, through the can-
didate approach by studying the rare mutations, several
genes have been identified as genes that are associated
with type 2 diabetes and obesity. These genes and the
studies are summarized in Table 2.
Prevention of type 2 diabetes
Because of the devastating negative economic impact and
human cost of type 2 diabetes, it is highly desirable that
this disease can be prevented. Proof-of-concept studies for
the prevention of type 2 diabetes have been conducted in
several clinical trials in recent years. The outcome of these
trials provide convincing evidence that either through life-
style adjustment or through pharmacological treatment,
type 2 diabetes can be prevented or, at least, be delayed.
This conclusion is of profound implication in our way of
thinking about the diabetes treatment and about the
direction of finding new pharmacological entity as well as
policy changes in the health care system.
There are four randomized controlled trials reported to-
date for lifestyle modification. The conclusions from these
studies are in general supportive of each other, and
strongly argue for lifestyle modification as an effective
way to prevent type 2 diabetes. The first study, Da Qing
Study, dates back to 1986 [57]. Individuals diagnosed
with IGT (577 patients) were randomized either to a con-
trol group or to one of three active treatment groups: diet
only, exercise only, or diet plus exercise. Follow-up evalu-
ation examinations were conducted at 2-year intervals
over a 6-year period to identify subjects who developed
type 2 diabetes. The cumulative incidence of diabetes at 6
years was 67.7%, 43.8%, 41.1%, and 46.0% in the control
group, diet group, exercise group, and diet-plus-exercise
group, respectively. After adjustment of BMI difference,
the diet, exercise, and diet-plus-exercise interventions
were associated with 31%, 46%, and 42% reductions in
risk of developing diabetes, respectively.
The second study was conducted in Finland. In the Finn-
ish trial [58], 522 middle-aged, overweight with impaired
glucose tolerance subjects were randomly assigned to
either the intervention group or the control group. The
intervention group received individualized counseling
aimed at reducing weight, total intake of fat, and intake of
saturated fat and increased intake of fiber and physical
activity. During the 3.2 years of follow-up, the cumulative
incidence of diabetes was 11% which was reduced by 52%
compared to the control group with an incidence of 23%.
In this time period, the risk of diabetes was reduced by
58% in the intervention group.
In the third study, the Diabetes Prevention Program [59],
a direct comparison was made between the lifestyle mod-
ification versus medication with metformin. Nondiabetic
candidates (3234) with elevated fasting and post-load
plasma glucose concentrations were randomized into pla-
cebo, metformin (850 mg twice daily), or a lifestyle-mod-
ification program (with the goals of at least a 7 percent
weight loss and at least 150 minutes of physical activity
per week). After a follow-up of 2.8 years, the incidence of
diabetes was 11.0%, 7.8%, and 4.8% each year in the pla-
cebo, metformin, and lifestyle groups, respectively. The
lifestyle intervention reduced the incidence by 58% and
metformin by 31%, as compared with placebo; the life-
style intervention was significantly more effective than
metformin.
More recently, a fourth study comparing lifestyle modifi-
cation and metformin medication was conducted in India
[60]. A cohort of 531 subjects with IGT were randomized
into four groups: control, lifestyle modification, met-
formin, lifestyle modification in addition to metformin.
Diabetes developed in 49.6%, 35%, 39.8% and 34.7%
respectively after 30 months of follow-up. This study adds
another piece of evidence that lifestyle modification is
effective in preventing diabetes. It also concluded that the
lifestyle modification effect is not enhanced by met-
formin.
The success of these major diabetes prevention trials has
impacted the way of approaching diabetes care. The ADA
has recommended that all overweight people, aged ≥ 45
years with prediabetes be considered potential candidates
for diabetes prevention. Overweight younger individuals
with prediabetes and other risk factors should also be
inducted into a diabetes prevention program [61].
Lifestyle modification
The success of the DPP and other trials provide compel-
ling evidence that modification of lifestyle, including
increasing exercise along with decreased caloric intake, is
an effective way of preventing or delaying the onset of
type 2 diabetes in high risk populations. Interestingly, the
pharmacological agent, metformin, only provided a mod-
est effect in the DPP trial. Furthermore, there was no addi-
tional benefit of metformin over the lifestyle modification
in its effect on diabetes prevention. Since the metformin
mechanism of action might be through activation of
AMPK [62], a kinase that is activated during exercise [63],
it is possible that exercise may act through the same
molecular cellular pathway and therefore there are no
additive effects of these two treatment regimens.
One important aspect of combating the epidemics of
obesity and type 2 diabetes has been through dietary strat-
egy. Recently, very-low-carbohydrate diets have gained
much popularity [64-67]. These diets have produced
results at least comparable to and frequently better thanNutrition & Metabolism 2005, 2:29 http://www.nutritionandmetabolism.com/content/2/1/29
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traditional diets [68-70] although their acceptance among
official agencies is limited at best. More recently the effects
of low-carbohydrate/high-protein diets on the blood glu-
cose levels, insulin resistance have been evaluated in
obese/over-weight type 2 diabetes patients. One study
comprised inpatient comparisons of a low-carbohydrate
diet (20 g carbohydrate per day and unlimited protein and
fat) among 10 obese patients with type 2 diabetes versus
another 10 patients in a usual diet for 14 days. On the
low-carbohydrate diet, mean energy intake decreased
from 3111 kcal/d to 2164 kcal/d. This resulted in a mean
weight loss of 1.65 kg, decrease in hemoglobin A1c from
7.3% to 6.8%, and insulin sensitivity improvement by
about 75% [71]. The other study used a moderately low
carbohydrate diet with a carbohydrate:protein:fat ratio of
20:30:50. Ingestion of this diet for 5 weeks in patients of
untreated type 2 diabetes decreased hemoglobin A1c from
~9.8% to ~7.6% [72]. These study seem to indicate, by
solely decrease the carbohydrate intake, it empowers
patients with diabetes to ameliorate hyperglycemia with-
out pharmaceutical intervention. Because glucose is the
major insulin secretagogue carbohydrate reduction would
be expected to be beneficial in type 2 diabetes and the use
of such diets has been summarized by Arora & McFarlane
[64] although, as noted above, official recommendations
generally continue to recommend low fat and high carbo-
hydrate intake.
Medications in diabetes prevention
Although lifestyle modification is the most effective way
of preventing diabetes in the clinical trials, the implemen-
tation demands a high level of discipline for the patients,
which may preclude its effectiveness in the general popu-
lation. In the long run, safe, effective medications, there-
fore, will likely be the best choice for intervention. One
important lesson from the success of prevention trials is
that lifestyle modification that results into the weight
change has proven to disrupt the apparent pathological
connection of overweight and the development of type 2
diabetes. Any drug that reduces weight increases the dis-
posal of excess energy, or mimics exercise could be an
effective treatment for diabetes prevention. The potential
non-pharmaceutical approach and the pharmaceutical
approach of diabetes prevention are summarized in table
3.
Anti-obesity drugs
The concept of using an anti-obesity strategy to prevent
diabetes was dramatically demonstrated in the follow-up
studies for clinically severe obese (> 45 kg excess body
weight) patients that received bariatric surgery [73]. Dur-
ing the ~5 year follow-up, among the experimental group
of patients that included 109 patients with IGT who
underwent bariatric surgery for weight loss, only 1 patient
developed diabetes, resulting in a conversion rate of only
0.15 cases per 100 person-years. This rate is 30 fold lower
than that found in the control group where the rate was
found to be 4.72 cases per 100 person-years. In another
prospective study conducted in Sweden, the Swedish
Obese Subjects (SOS) study, compared the incidence of
development of diabetes for 346 patients receiving gastric
bypass surgery to the same number of obese control sub-
jects receiving "conventional nonpharmacological obesity
treatment" [74]. For these two sets of clinically obese
patients, during the 8-year follow-up, the conventional
nonpharmacological obesity treatment, in the hands of a
primary health care system, had no effect on body weight,
whereas gastric bypass surgery resulted in 18- to 30-kg
maintained weight loss. This intentional weight loss in
severely obese individuals reduces the 8-year incidence of
diabetes by 5-fold. In addition to the benefit illustrated in
the dramatic weight loss, modest weight control also
added the benefit for diabetes prevention [75,76].
Orlistat (Xenical) is one of the few existing anti-obesity
drugs in the market. In 2004, after the completion of a
double-blind, placebo-controlled prospective study
known as Xenical in the Prevention of Diabetes in Obesity
Subjects (XENDOS), the European Commission
approved labelling for the reduction of risks associated
with the development of type 2 diabetes. In this study,
3,305 obese patients were followed over a 4-year period.
Patients who received orlistat not only lost more weight,
compared with those receiving placebo (5.7 kg vs. 3.0 kg),
but also exhibited a 37% reduction in the incidence of
type 2 diabetes during the treatment period [77]. Addi-
tional data indicated that orlistat reduced the doses of
antidiabetic drugs by 23% during the treatment [78].
However, the profound gastrointestinal negative side
effects of orlistat (such as oily spotting, flatus with dis-
charge, fecal urgency) cause inconsistent compliance. This
greatly reduces the use of this anti-obesity drug for the pre-
vention of diabetes.
Rimonobant, the first selective cannabinoid type 1 (CB1)
receptor antagonist, developed as an anti-obesity agent, is
nearly completing phase III clinical trials. Originally, it
was assumed that a CB1 antagonist would primarily
reduce the food intake through a central nervous system-
mediated effects [79,80]. Recent emerging evidence in
experimental animals clearly indicate that the reduction
of body weight and fat mass effected by CB1 antagonists
is also due to peripheral mechanisms [81]. These may
include a decrease in lipogenesis [82] and an increase in
fatty acid oxidation [83]. The data from clinical trials of
rimonobant further suggests that the weight loss, derived
from the combined anorectic effect and the peripheral
healthy effects in modulating fat metabolism, may have
benefit for the treatment of Metabolic Syndrome.
Rimonabant in Obesity Europe (RIO Europe) is the first ofNutrition & Metabolism 2005, 2:29 http://www.nutritionandmetabolism.com/content/2/1/29
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four Phase III studies whose partial data have been
revealed [84]. Results of the RIO Europe program indicate
that rimonabant at 20 mg/day, is associated with a signif-
icant decrease in body weight, as well as with a substantial
mobilization of abdominal adipose tissue as indicated by
a considerable reduction in waist circumference. Further-
more, the administration of rimonabant produced bene-
ficial metabolic effects on plasma lipid parameters and on
the glycemic profile, including the improvement in insu-
lin sensitivity. Thus, these improvements decrease several
parameters which comprise the metabolic syndrome in
the patient population. As RIO Europe is continuing, it is
much anticipated that rimonabant treatment will have
significant effect on reducing the incidence of type 2 dia-
betes among the ~1000 patients with BMI ≥ 30 kg/m2.
Other mechanisms for diabetes prevention
In the original design of the DPP trial, troglitazone, a syn-
thetic agonist of peroxisome proliferator-activated recep-
tor (PPAR)-γ, known for its insulin-sensitizing effect, was
included as an independent therapeutic arm [85]. Due to
the concern of liver toxicity of troglitazone, this arm was
discontinued in 1998 [86]. Using the "short-term" data
derived from the mean 0.9 year of troglitazone treatment,
the diabetes incidence rate was estimated to be 3.0 cases/
100 person-years, compared with 12.0, 6.7, and 5.1 cases/
100 person-years in the placebo, metformin, and lifestyle
modification participants [86]. The delay of diabetes by
troglitazone was associated with preservation of β-cell
compensation for insulin resistance [87]. The therapeutic
benefit of troglitazone appeared to be reversible. During
the 3 years after troglitazone withdrawal, the diabetes
incidence rate bounced back to a level similar to the pla-
cebo group [86]. According to these data, insulin sensiti-
zation through a PPAR-γ activation mechanism is effective
in diabetes prevention. However the availability of an
agent with an appropriate safety property remains to be a
challenge for long term and wide uses.
Acarbose, an α-glucosidase inhibitor, that inhibits the
hydrolysis of non-absorbable oligosaccharides and
polysaccharides into absorbable monosaccharides which
takes place in the brush border of enterocytes, is another
agent that is efficacious in reducing blood glucose and
insulin level, especially in the postprandial conditions. In
the STOP-NIDDM trial, the effect of Acarbose in prevent-
ing or delaying the development of type 2 diabetes was
assessed [88]. In this multicenter, placebo-controlled ran-
domised trial, patients with IGT were randomly allocated
to 100 mg acarbose or placebo three times daily. After a
mean follow-up of 3.3 years, 32% patients randomised to
acarbose and 42% randomised to placebo developed dia-
betes. Furthermore, acarbose significantly increased rever-
sion of impaired glucose tolerance to normal glucose
tolerance. It was concluded that Acarbose could be used,
either as an alternative or in addition to changes in life-
style, to delay development of type 2 diabetes in patients
with IGT.
If preservation of β-cell compensation is an effective way
to prevent the progression of type 2 diabetes, strategies
based on glucagons-like peptide (GLP) -1 should be suc-
cessful as well. GLP-1 is an incretin hormone stimulating
the glucose-induced insulin secretion in pancreatic β-cells
[89]. It not only stimulates the biosynthesis and exocyto-
sis of insulin, but it also has effects on β-cell growth and
survival that lead to increased β-cell mass. Moreover, GLP-
1 also inhibits the motility in the gastrointestinal tract
which slows down the passage of nutrients to the small
intestine. When administered in peripheral, GLP-1 also






Drugs Molecular Target Site(s) of Action Clinically Proven
Metformin Unknown Liver (muscle) Yes
Acarbose α-glucosidase Intestine Yes
Olistat lipase Intestine Yes
Thiazolidinediones PPARγ Liver, fat, muscle Yes
Rimonobant CB-1 Brain (fat, liver) No
DPP4 inhibitors DPP4 pancreatic islet beta-cells No
GLP1 analogs GLP1-receptor pancreatic islet beta-cells NoNutrition & Metabolism 2005, 2:29 http://www.nutritionandmetabolism.com/content/2/1/29
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increases the satiety level [90]. In the clinic, a synthetic
GLP-1 receptor agonist with a pro-longed half-life com-
pared to the endogenous GLP-1 significantly improved
HbA1C [91] along with obvious weight reduction in the
patients [92]. Inhibitors of dipeptidyl peptidase (DPP) IV,
a protease responsible for the degradation of short-lived
endogenous GLP-1, not only extended the half-life of this
incretin hormone, but also reduced the excursion of glu-
cose in diabetic patients [93]. These data demonstrate that
GLP-1 based therapies, either through administration of
exogenous synthetic GLP-1 receptor agonists or through
inhibiting DPP IV, are effective in diabetes treatment.
Whether these strategies will be successful in pre-diabetes
patients to prevent or to delay the onset of type 2 diabetes,
awaits more clinical studies designed to address the issue.
Concluding thoughts
Both the diabetes and the obesity epidemics have posed
serious assaults on health care. It is anticipated that it will
be an uphill battle to fight these ever increasing epidem-
ics, especially since, individually, these conditions are dif-
ficult to treat. However, considering the history in the
advances of modern medicine, the future looks brighter.
The pharmaceutical breakthrough of the statin-class of
safe and effective drugs for plasma cholesterol control has
caused the mortality rate for cardiovascular disease to
decrease [94,95]. The economic benefits have also been
demonstrated [96]. Today, there is wide public awareness
that obesity and a sedentary lifestyle are culprits leading to
the development of diabetes. It is generally known that
modifying the sedentary lifestyle with exercise can have a
positive impact on diabetes. There are also active efforts in
modulating the dietary composition, particularly through
cutting down carbohydrates, in the public. What is lacking
presently is a true breakthrough for a safe and effective
way to treat weight problems. The good news is that there
are many appetite suppressant drugs and other anti-obes-
ity drugs in discovery pipelines of the pharmaceutical
industry. As more of these future drugs move forward in
the pipeline and eventually to the market, it is possible to
be optimistic that an era of type 2 diabetes prevention
may be about to begin.
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